Oslo Myeloma Center

F. Schjesvold<br>Group leader
F. Schjesvold
Group leader

Group leader: Fredrik Schjesvold, MD
Associated research doctors: Nina Gulbrandsen, MD PhD, Puneet Kaur, Magnus MoksnesAnne Elisabeth Tonay Carlsen
Research coordinator: Anna Lysén
Study nurses: Ulla MadsenMarrydith Tran, Kristin Låstad, Larisa MyrsethEsther Morilla, Hedda Nyhus, Sylvia Rognli og Ann-Kristin Mitchell
Study secretaries: Ann Døli, Liv Sigrun Eide, Anita Husøy


About our research:


Oslo Myeloma Center is the largest center for clinical myeloma research in the Nordics, with about 70-80 newly included patients a year. In 2016, nine studies have included patients, in young and elderly, in newly diagnosed and in patients with one or multiple relapses. We cooperate with basal and translational research groups, providing them with fresh cellular samples. In addition, we are creating a myeloma registry with a new database created by Medinsight




Ongoing trials:

  • NMSG#20/13 - Carfilzomib-based ASCT for relapsed myeloma
  • Magnolia - Zoledronic acid 2 years vs 4 years
  • Panorama 3: Panobinostat-Velcade-Dexamethason randomized to different doses in relapse treatment
  • HOVON129 - Treatment of primary plasma cell leukemia
  • CA209-602: Elotuzumab, Nivolumab og Pomalidomid for >2 previous treatments
  • IsatuximabPomDex vs PomDex 3.linje og utover

  • Melflufen mot Pomalidomid 3 linje og utover

Upcoming trials:

  • Ixazomib-Revlimid-Dexamethason in first line for the young
  • Carfilzomib-Revlimid-Dexamethasone as consolidation after first line therapy
  • Daratumumab in smouldering myeloma
  • Ixazomib vs Pomalidomide in relapsed myeloma
  • Melflufen vs Pomalidomide in relapsed myeloma
  • APO010 in drug sensitive relapsed myeloma
  • Cometinib +/- venetoclax +/- atezolizumab in relapsed myeloma